Today: 20 May 2026
UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom
9 February 2026
1 min read

UnitedHealth stock price today: UNH ticks up as Medicare Advantage rates and U.S. data loom

New York, February 9, 2026, 11:39 EST — Regular session

UnitedHealth Group Incorporated (UNH) inched up 0.3% to $277.44 by late morning Monday. Shares moved within a range of $273.88 to $278.36.

Even a tiny change like that matters, since UNH’s fortunes are still tightly linked to Medicare Advantage—those private senior and disability plans shaped by federal payment policies. The Centers for Medicare & Medicaid Services has floated its 2027 Advance Notice, flagging just a 0.09% bump in average payments. Comments are open through Feb. 25, and the agency is due to lock in the final rate by April 6.

Stocks in the U.S. got off to a mixed start this morning. Investors kept an eye on interest rate signals following last week’s tech slump. The Dow slipped roughly 0.3%. The S&P 500 was little changed, while the Nasdaq managed a slight uptick, according to Reuters.

UnitedHealth posted 2025 revenue of $447.6 billion on Jan. 27, a 12% increase, and projected 2026 revenue to top $439.0 billion with adjusted earnings expected to exceed $17.75 per share. CEO Stephen Hemsley, in prepared comments, said the company “confronted challenges directly” and wrapped up 2025 “as a much stronger company.” UnitedHealth Group

Investors didn’t like the news: shares dropped up to 19% on Jan. 27 after the company signaled its first revenue drop since 1989, according to Reuters. Hemsley talked up noticeable “momentum” inside the company, but UnitedHealthcare chief Tim Noel flagged “meaningful benefit reductions” coming. Morningstar’s Julie Utterback told investors looking for a fast turnaround they “may have to wait longer than hoped.” For 2026, UnitedHealth projected its medical care ratio—how much of premiums go toward medical costs—at roughly 88.8%, an important profit metric for the sector. Reuters

UnitedHealth isn’t alone when it comes to rising costs. Molina Healthcare on Feb. 6 slashed its 2026 profit outlook, blaming higher medical expenses, and announced it will walk away from Medicare Advantage prescription drug plans in 2027. CEO Joseph Zubretsky called 2026 a “trough year” for Medicaid margins. Reuters

UNH faces a tough setup right now: reimbursement remains squeezed, and care utilization just won’t cool off. Insurers could try to prop up margins by cutting back on benefits or pulling back from certain markets—though moves like that risk slowing down membership gains and drawing extra attention.

Scrutiny isn’t new. Back in January, a Senate committee report accused UnitedHealth of employing aggressive risk-adjustment coding tactics—essentially, a method that increases payments for plans serving sicker Medicare Advantage patients—to ramp up reimbursement. The company pushed back, saying it disagreed with the report’s take and insists its programs follow regulations.

No obvious company news to kick things off Monday, so traders will be eyeing the U.S. macro calendar. First up: the January Employment Situation lands at 8:30 a.m. ET on Feb. 11. Just two days later, January’s Consumer Price Index hits at 8:30 a.m. ET on Feb. 13, per Labor Department schedules.

Stock Market Today

  • Okta (OKTA) Stock Declines Amid Market Despite Strong Earnings Outlook
    May 19, 2026, 7:32 PM EDT. Okta (OKTA) shares fell 1.68% to $74.45, underperforming the S&P 500's slight 0.02% decline. The cloud identity management firm is expected to report earnings per share (EPS) of $0.57, a 29.55% increase year-over-year, and revenue of $649.35 million, up 11.19%. Annual forecasts predict EPS of $2.61 and revenue of $2.56 billion, marking increases of 63.13% and 13.19%, respectively. Despite the recent stock drop, Okta holds a Zacks Rank #1 (Strong Buy), reflecting optimistic analyst revisions. The stock trades at a forward price-to-earnings ratio of 29.07, above the industry average of 17.59, and a PEG ratio of 1.26 compared to the industry's 1.58, indicating valuation relative to earnings growth.

Latest articles

James Hardie Drops After Warning on Housing, Even With Q4 Beat

James Hardie Drops After Warning on Housing, Even With Q4 Beat

20 May 2026
James Hardie’s U.S.-listed shares dropped 6.1% Tuesday and slid another 2.6% after hours after reporting a 35% fall in quarterly net income to $28.5 million, despite a 45% jump in net sales to $1.40 billion. The company cited weak housing demand and warned the market remains uncertain. ASX shares had not traded post-earnings; they last closed at A$26.78, up 2.9%.
SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

20 May 2026
SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
Red Robin Shares Rise After Earnings Beat

Red Robin Shares Rise After Earnings Beat

20 May 2026
Red Robin shares surged 15.6% after hours to $4.45 Tuesday, following first-quarter revenue of $378.3 million that beat Wall Street estimates despite a 0.6% drop in comparable sales and a 1.6% decline in guest traffic. Net loss was $2.2 million, or 12 cents per share. The company reaffirmed its 2026 outlook and said refranchising talks are in final stages.
AI stocks brace for a big week: Micron slips on Samsung HBM4 talk as Nvidia looms
Previous Story

AI stocks brace for a big week: Micron slips on Samsung HBM4 talk as Nvidia looms

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution
Next Story

India fintech MIDASX hits best quarter, turns cash-flow positive as it scales AI-led distribution

Go toTop